tiprankstipranks
Trending News
More News >

Noxopharm Advances Drug Development with Key Agreements and Preclinical Success

Story Highlights
  • Noxopharm signed a follow-on MTA, showing increased interest in its Sofra technology.
  • SOF-SKN™ passed preclinical tests, moving closer to clinical trials for autoimmune diseases.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Noxopharm Advances Drug Development with Key Agreements and Preclinical Success

Don’t Miss TipRanks’ Half-Year Sale

Noxopharm Ltd. ( (AU:NOX) ) has provided an announcement.

Noxopharm Limited has announced significant progress in its quarterly activities, including a follow-on Material Transfer Agreement with an international company, highlighting growing interest in its Sofra technology platform. The company also reported that its novel drug candidate, SOF-SKN™, successfully passed preclinical tests, paving the way for a clinical trial aimed at treating autoimmune diseases like lupus. These developments position Noxopharm to capitalize on the expanding global RNA market and strengthen its industry standing.

More about Noxopharm Ltd.

Noxopharm Limited is an Australian drug development company focused on creating innovative treatments for autoimmune diseases and leveraging its Sofra technology platform for vaccines and therapeutics. The company is actively involved in collaborations with international partners and research institutes to expand its market presence.

YTD Price Performance: -14.44%

Average Trading Volume: 93,652

Technical Sentiment Signal: Buy

Current Market Cap: A$22.5M

Learn more about NOX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1